Review

Growth hormone as a treatment for post-stroke recovery: a review of preclinical and clinical evidence

  • Published: 06 November 2026
  • Despite advances in acute stroke management, many survivors experience lasting motor and cognitive long-term sequelae. Acute reperfusion therapies and prevention strategies are well established, but options to enhance long-term motor and cognitive recovery remain limited. Several pharmacologic adjuncts (selective serotonin reuptake inhibitors (SSRIs), cholinesterase inhibitors, memantine) have shown inconsistent efficacy or safety, highlighting an unmet need for effective post-stroke recovery therapies. Growth hormone (GH) has emerged as a candidate adjunctive therapy based on its neurotrophic properties and the discovery of an endogenously activated neural GH axis following brain injury. This review aims to summarize GH's proposed mechanisms to promote neurorecovery after a stroke and to synthesize preclinical and clinical evidence supporting its use as an adjunct to standard post-stroke rehabilitation. A narrative review of preclinical and clinical studies that examined GH administration following ischemic stroke was conducted, emphasizing functional, cognitive, and safety outcomes; mechanistic findings connecting GH to neurotrophic signaling, synaptic plasticity, and cerebrovascular remodeling are also discussed. Preclinical studies demonstrated that GH administration after a stroke accelerates motor recovery, improves spatial and associative memory, reduces peri-infarct tissue loss, and increases neurotrophic, synaptic, and angiogenic markers (BDNF, IGF-1, VEGF). Four human clinical trials, along with the phase I-II COURAGE trial of GH-secretagogue therapy, reported significant improvements in functional independence (Korean Modified Barthel Index (K-MBI), motor and cognitive scores (Fugl-Meyer, Montreal Cognitive Assessment), and reduced neurological deficit (Modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS) in GH-treated patients compared with controls, without serious adverse events. Preclinical and early clinical evidence supports GH as a promising and safe adjunct to standard post-stroke rehabilitation, particularly for enhancing motor and cognitive recovery; however, existing clinical trials are small and varied in design, and larger, multicenter randomized controlled trials are required to establish optimal dosing, timing, and treatment duration before GH can be incorporated into standard post-stroke care.

    Citation: Emmanuelle Zakheim, Daniel Moon, Wesley Tran, Ephrem Gerald, Mohamed Ahmed. Growth hormone as a treatment for post-stroke recovery: a review of preclinical and clinical evidence[J]. AIMS Neuroscience, 2026, 13(4): 651-666. doi: 10.3934/Neuroscience.2026030

    Related Papers:

  • Despite advances in acute stroke management, many survivors experience lasting motor and cognitive long-term sequelae. Acute reperfusion therapies and prevention strategies are well established, but options to enhance long-term motor and cognitive recovery remain limited. Several pharmacologic adjuncts (selective serotonin reuptake inhibitors (SSRIs), cholinesterase inhibitors, memantine) have shown inconsistent efficacy or safety, highlighting an unmet need for effective post-stroke recovery therapies. Growth hormone (GH) has emerged as a candidate adjunctive therapy based on its neurotrophic properties and the discovery of an endogenously activated neural GH axis following brain injury. This review aims to summarize GH's proposed mechanisms to promote neurorecovery after a stroke and to synthesize preclinical and clinical evidence supporting its use as an adjunct to standard post-stroke rehabilitation. A narrative review of preclinical and clinical studies that examined GH administration following ischemic stroke was conducted, emphasizing functional, cognitive, and safety outcomes; mechanistic findings connecting GH to neurotrophic signaling, synaptic plasticity, and cerebrovascular remodeling are also discussed. Preclinical studies demonstrated that GH administration after a stroke accelerates motor recovery, improves spatial and associative memory, reduces peri-infarct tissue loss, and increases neurotrophic, synaptic, and angiogenic markers (BDNF, IGF-1, VEGF). Four human clinical trials, along with the phase I-II COURAGE trial of GH-secretagogue therapy, reported significant improvements in functional independence (Korean Modified Barthel Index (K-MBI), motor and cognitive scores (Fugl-Meyer, Montreal Cognitive Assessment), and reduced neurological deficit (Modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS) in GH-treated patients compared with controls, without serious adverse events. Preclinical and early clinical evidence supports GH as a promising and safe adjunct to standard post-stroke rehabilitation, particularly for enhancing motor and cognitive recovery; however, existing clinical trials are small and varied in design, and larger, multicenter randomized controlled trials are required to establish optimal dosing, timing, and treatment duration before GH can be incorporated into standard post-stroke care.


    Abbreviations

    ALFF

    Amplitude of Low-Frequency Fluctuations

    BBB

    Blood-Brain Barrier

    BDNF

    Brain-Derived Neurotrophic Factor

    BID

    Bis In Die (twice daily)

    BOLD

    Blood-Oxygen-Level-Dependent

    BrdU

    Bromodeoxyuridine

    BUN

    Blood Urea Nitrogen

    CBC

    Complete Blood Count

    CD31

    Cluster of Differentiation 31

    CT

    Computed Tomography

    DCX

    Doublecortin

    DEXA

    Dual-Energy X-ray Absorptiometry

    DMN

    Default Mode Network

    EGF

    Epidermal Growth Factor

    ET-1

    Endothelin-1

    FAC

    Functional Ambulation Category

    FC

    Functional Connectivity

    FMA

    Fugl-Meyer Assessment

    fMRI

    Functional Magnetic Resonance Imaging

    GH

    Growth Hormone

    GH3

    Growth Hormone, 3-month treatment group

    GH6

    Growth Hormone, 6-month treatment group

    GHR

    Growth Hormone Receptor

    GHRP-6

    Growth Hormone-Releasing Peptide 6 (Growth Hormone-Releasing Hexapeptide)

    HbA1c

    Hemoglobin A1c

    ICV

    Intracerebroventricular

    IGF-1

    Insulin-like Growth Factor-1

    IV

    Intravenous

    K-MBI

    Korean Modified Barthel Index

    K-MMSE

    Korean Mini-Mental State Examination

    LDL(-C)

    Low-Density Lipoprotein (Cholesterol)

    MBP

    Myelin Basic Protein

    MI

    Motricity Index

    MMT

    Manual Muscle Test/Strength

    MoCA

    Montreal Cognitive Assessment

    mRS

    Modified Rankin Scale

    mTOR

    Mechanistic (Mammalian) Target of Rapamycin

    NeuN

    Neuronal Nuclei (neuronal marker)

    NIHSS

    National Institutes of Health Stroke Scale

    NS

    Not Significant

    OR

    Odds Ratio

    p70S6K

    p70 S6 Kinase

    PAL

    Paired-Associate Learning (task)

    PSD-95

    Postsynaptic Density Protein 95

    RCT

    Randomized Controlled Trial

    rhGH

    Recombinant Human Growth Hormone

    rTMS

    Repetitive Transcranial Magnetic Stimulation

    SAE(s)

    Serious Adverse Event(s)

    SC

    Subcutaneous

    SVZ

    Subventricular Zone

    SYN-1

    Synapsin-1

    tDCS

    Transcranial Direct Current Stimulation

    TBI

    Traumatic Brain Injury

    TG

    Triglycerides

    VA/DoD

    Veterans Affairs/Department of Defense

    VEGF

    Vascular Endothelial Growth Factor

    加载中

    Acknowledgments



    David Moon for help in designing and illustration of the original image, Figure 1.



    Conflict of interest



    The authors declare no conflict of interest.



    Authors' contributions



    Emmanuelle Zakheim: conceptualization, investigation, writing- original draft, writing-review and editing; Daniel Moon: investigation, writing-original draft, writing-review and editing; Wesley Tran: investigation, writing-review and editing; Ephrem Gerald: investigation, writing-reviewing and editing; Mohamed Ahmed: conceptualization, supervision, writing-reviewing and editing. All authors have read and agreed to the published version of the manuscript.



    [1] GBD 2021 Stroke Risk Factor Collaborators.Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol (2024) 23: 973-1003. https://doi.org/10.1016/S1474-4422(24)00369-7
    [2] Ho JP, Powers WJ (2025) Contemporary management of acute ischemic stroke. Annu Rev Med 76: 417-429. https://doi.org/10.1146/annurev-med-050823-094312
    [3] Mac Grory B, Xian Y, Solomon NC, et al. (2021) Exploring the unmet need in acute ischemic stroke patients not treated with intravenous alteplase: The get with the guidelines-stroke registry. Stroke Vasc Interv Neurol 2: e000226. https://doi.org/10.1161/SVIN.121.000226
    [4] Li X, Wu M, Zhang J, et al. (2025) Post-stroke dysphagia: Neurological regulation and recovery strategies. Biosci Trends 19: 31-52. https://doi.org/10.5582/bst.2025.01029
    [5] Huang J, Ji JR, Liang C, et al. (2022) Effects of physical therapy-based rehabilitation on recovery of upper limb motor function after stroke in adults: a systematic review and meta-analysis of randomized controlled trials. Ann Palliat Med 11: 521-531. https://doi.org/10.21037/apm-21-3710
    [6] Chen B, Yang T, Liao Z, et al. (2025) Pathophysiology and management strategies for post-stroke spasticity: An update review. Int J Mol Sci 26: 406. https://doi.org/10.3390/ijms26010406
    [7] Winstein CJ, Stein J, Arena R, et al. (2016) Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 47: e98-e169. https://doi.org/10.1161/STR.0000000000000098
    [8] Eapen BC, Tran J, Ballard-Hernandez J, et al. (2025) Stroke Rehabilitation: Synopsis of the 2024 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines. Ann Intern Med 178: 249-268. https://doi.org/10.7326/ANNALS-24-02205
    [9] Robinson RG, Jorge RE (2016) Post-stroke depression: a review. Am J Psychiatry 173: 221-231. https://doi.org/10.1176/appi.ajp.2015.15030363
    [10] El Husseini N, Katzan IL, Rost NS, et al. (2023) Cognitive impairment after ischemic and hemorrhagic stroke: a scientific statement from the American Heart Association/American Stroke Association. Stroke 54: e272-e291. https://doi.org/10.1161/STR.0000000000000430
    [11] Zhou Y, Feng H, Li G, et al. (2022) Efficacy of computerized cognitive training on improving cognitive functions of stroke patients: A systematic review and meta-analysis of randomized controlled trials. Int J Nurs Pract 28: e12966. https://doi.org/10.1111/ijn.12966
    [12] Amalia L (2026) Role of non-invasive brain stimulation with repetitive transcranial magnetic stimulation in improving fine motor performance of post-stroke patients: A systematic review and meta-analysis. BMC Neurol 26: 339. https://doi.org/10.1186/s12883-026-04839-z
    [13] Schlaug G, Renga V, Nair D (2008) Transcranial direct current stimulation in stroke recovery. Arch Neurol 65: 1571-1576. https://doi.org/10.1001/archneur.65.12.1571
    [14] U.S. Department of Veterans AffairsVA/DoD clinical practice guideline for management of stroke rehabilitation* (Version 5.0) (2024). Available from: https://www.healthquality.va.gov/guidelines/rehab/stroke/index.asp
    [15] Sanchez-Bezanilla S, Åberg ND, Crock P, et al. (2020) Growth hormone promotes motor function after experimental stroke and enhances recovery-promoting mechanisms within the peri-infarct area. Int J Mol Sci 21: 606. https://doi.org/10.3390/ijms21020606
    [16] Shin DH, Lee E, Kim JW, et al. (2004) Protective effect of growth hormone on neuronal apoptosis after hypoxia-ischemia in the neonatal rat brain. Neurosci Lett 354: 64-68. https://doi.org/10.1016/j.neulet.2003.09.070
    [17] Song J, Park K, Lee H, et al. (2012) The effect of recombinant human growth hormone therapy in patients with completed stroke: a pilot trial. Ann Rehabil Med 36: 447-457. https://doi.org/10.5535/arm.2012.36.4.447
    [18] Legg LA, Rudberg AS, Hua X, et al. (2021) Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database of Systematic Reviews . https://doi.org/10.1002/14651858.CD009286.pub4
    [19] Shenkin SD, Hewitt J, Quinn TJ (2021) Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database of Systematic Reviews . https://doi.org/10.1002/14651858.CD013306.pub2
    [20] Donato J, Kopchick JJ (2024) New findings on brain actions of growth hormone and potential clinical implications. Rev Endocr Metab Disord 25: 541-553. https://doi.org/10.1007/s11154-023-09861-x
    [21] Scheepens A, Sirimanne E, Beilharz E, et al. (1999) Alterations in the neural growth hormone axis following hypoxic-ischemic brain injury. Mol Brain Res 68: 88-100. https://doi.org/10.1016/S0169-328X(99)00051-0
    [22] Devesa P, Agasse F, Xapelli S, et al. (2014) Growth hormone pathways signaling for cell proliferation and survival in hippocampal neural precursors from postnatal mice. BMC Neurosci 15: 100. https://doi.org/10.1186/1471-2202-15-100
    [23] Falleti MG, Maruff P, Burman P, et al. (2006) The effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults: a meta-analysis of the current literature. Psychoneuroendocrinology 31: 681-691. https://doi.org/10.1016/j.psyneuen.2006.01.005
    [24] Christophidis LJ, Gorba T, Gustavsson M, et al. (2009) Growth hormone receptor immunoreactivity is increased in the subventricular zone of juvenile rat brain after focal ischemia: A potential role for growth hormone in injury-induced neurogenesis. Growth Horm IGF Res 19: 497-506. https://doi.org/10.1016/j.ghir.2009.05.001
    [25] Scheepens A, Sirimanne ES, Breier BH, et al. (2001) Growth hormone as a neuronal rescue factor during recovery from CNS injury. Neuroscience 104: 677-687. https://doi.org/10.1016/S0306-4522(01)00109-9
    [26] Lillicrap T, Garcia-Esperon C, Walker FR, et al. (2018) Growth hormone deficiency is frequent after recent stroke. Front Neurol 9: 713. https://doi.org/10.3389/fneur.2018.00713
    [27] Popovic V (2005) GH deficiency as the most common pituitary defect after TBI: clinical implications. Pituitary 8: 239-243. https://doi.org/10.1007/s11102-006-6047-z
    [28] Ascoli P, Cavagnini F (2006) Hypopituitarism. Pituitary 9: 335-342. https://doi.org/10.1007/s11102-006-0416-5
    [29] Pathipati P, Surus A, Williams C E, et al. (2009) Delayed and chronic treatment with growth hormone after endothelin-induced stroke in the adult rat. Behav Brain Res 204: 93-101. https://doi.org/10.1016/j.bbr.2009.05.023
    [30] Ong LK, Chow WZ, TeBay C, et al. (2018) Growth hormone improves cognitive function after experimental stroke. Stroke 49: 1257-1266. https://doi.org/10.1161/STROKEAHA.117.020557
    [31] Sanchez-Bezanilla S, Beard DJ, Hood RJ, et al. (2022) Growth hormone increases BDNF and mTOR expression in specific brain regions after photothrombotic stroke in mice. Neural Plast 2022: 9983042. https://doi.org/10.1155/2022/9983042
    [32] Devesa P, Reimunde P, Gallego R, et al. (2011) Growth hormone (GH) treatment may cooperate with locally-produced GH in increasing the proliferative response of hippocampal progenitors to kainate-induced injury. Brain Inj 25: 503-510. https://doi.org/10.3109/02699052.2011.559611
    [33] Hong I, Lim Y, Han HS, et al. (2017) Application of the Korean Version of the Modified Barthel Index: Development of a keyform for use in Clinical Practice. Hong Kong J Occup Ther 29: 39-46. https://doi.org/10.1016/j.hkjot.2017.06.001
    [34] Han JS, Ryu SM, Lim YH, et al. (2024) Is the Korean mini-mental state examination (K-MMSE) useful in evaluating the cognitive function of brain injury patients?: Through correlation analysis with computerized neurocognitive test (CNT). Brain Neurorehabil 17: e13. https://doi.org/10.12786/bn.2024.17.e13
    [35] Jin GH, Lee JB (2018) Effect of recombinant human growth hormone add on therapy on acute stroke outcome. Brain Neurorehabil 11: e4. https://doi.org/10.12786/bn.2018.11.e4
    [36] Feng X, Li G, Wu W, et al. (2020) Recombinant human growth hormone ameliorates cognitive impairment in stroke patients. J Comput Assist Tomogr 44: 255-261. https://doi.org/10.1097/RCT.0000000000000990
    [37] Hernández-Bernal F, Estenoz-García D, Gutiérrez-Ronquillo JH, et al. (2024) Combination therapy of Epidermal Growth Factor and Growth Hormone-Releasing Hexapeptide in acute ischemic stroke: a phase I/II non-blinded, randomized clinical trial. Front Neurol 15: 1303402. https://doi.org/10.3389/fneur.2024.1303402
  • Reader Comments
  • © 2026 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)

Metrics

Article views(200) PDF downloads(8) Cited by(0)

Article outline

Figures and Tables

Figures(1)  /  Tables(2)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog